The Korean journal of internal medicine

  • 제28권6호
  • /
  • Pages.654-656
  • /
  • 2013
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

A biomarker, osteoprotegerin, in patients undergoing hemodialysis

  • Ko, Gang Jee (Division of Nephrology, Department of Internal Medicine, Korea University College of Medicine)
  • 투고 : 2013.08.31
  • 심사 : 2013.09.10
  • 발행 : 2013.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Aoki A, Murata M, Asano T, et al. Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. Cardiovasc Diabetol 2013;12:11. https://doi.org/10.1186/1475-2840-12-11
  2. Kiechl S, Werner P, Knof lach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006;4:801-811. https://doi.org/10.1586/14779072.4.6.801
  3. Montagnana M, Lippi G, Danese E, Guidi GC. The role of osteoprotegerin in cardiovascular disease. Ann Med 2013;45:254-264. https://doi.org/10.3109/07853890.2012.727019
  4. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-3545. https://doi.org/10.1073/pnas.96.7.3540
  5. Lee JE, Kim HJ, Moon SJ, et al. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients. Korean J Intern Med 2013;28:668-677. https://doi.org/10.3904/kjim.2013.28.6.668
  6. Lieb W, Gona P, Larson MG, et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849-1854. https://doi.org/10.1161/ATVBAHA.109.199661
  7. Pateinakis P, Papagianni A, Douma S, Efstratiadis G, Memmos D. Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol 2013;14:122. https://doi.org/10.1186/1471-2369-14-122
  8. Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4: another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant 2012;27:727-733. https://doi.org/10.1093/ndt/gfr316
  9. Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006;17:262-270. https://doi.org/10.1681/ASN.2006080924
  10. Janda K, Krzanowski M, Chowaniec E, et al. Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. Pol Arch Med Wewn 2013;123:149-155.
  11. Bennett BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006;26:2117-2124. https://doi.org/10.1161/01.ATV.0000236428.91125.e6
  12. Weiss RM, Lund DD, Chu Y, et al. Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice. PLoS One 2013;8:e65201. https://doi.org/10.1371/journal.pone.0065201
  13. Jiang JQ, Lin S, Xu PC, Zheng ZF, Jia JY. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. Nephrology (Carlton) 2011;16:588-594. https://doi.org/10.1111/j.1440-1797.2011.01481.x